Protara staff meeting - hero

tenacious in our search for transformative therapies

TARA-002

TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for multiple oncologic indications and lymphatic malformations (LMs). We are evaluating TARA-002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and LMs in the U.S.

IV CHOLINE CHLORIDE

An investigational phospholipid substrate replacement therapy for patients on parenteral nutrition (PN). Approximately 80% of PN patients are choline deficient and have some degree of liver damage. IV Choline Chloride has the potential to become the first FDA approved IV choline formulation for PN patients.

Scroll to Top